Kulkarni Samarth sold $2.4M of CRSP

Kulkarni Samarth (Chief Executive Officer) sold 47,837 shares of CRISPR Therapeutics AG (CRSP) at $49.78 ($2.38M total) on 2026-10-19.

Original reporting
SEC EDGAR · Kulkarni Samarth
Published Oct 20, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
high confidence
Mentioned
$CRSP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The $2.38 M sale reduces the CEO's ownership by ~13% and may trigger short‑term selling pressure.

02

Market read

Insider sell by the CEO provides fresh material for traders; could influence short‑term price action.

03

What to watch

No 10b5‑1 plan; the sale was not pre‑arranged, suggesting discretionary timing.

Relevance 6/10Novelty 6/10Timing: filed today (Oct 20)

Background

Form 4 filings disclose insider transactions; a CEO sale is closely watched by investors.

Company-level read

Ticker impact

$CRSPBearishHigh confidence
Context

CEO Kulkarni Samarth sold 47,837 shares for $2.38 M, reducing his stake to 311,899 shares.

Expected impact

likely downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 is a primary source; a $2.4 M sale by the CEO is material and new information.

Market effects

May raise concerns for the biotech sector if other insiders follow suit.

Limited to US and European markets where CRISPR trades.

Low; impact confined to CRISPR and its immediate peers.

Counterpoint

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Kulkarni Samarth

    Chief Executive Officer of CRISPR Therapeutics AG

  • CRISPR Therapeutics AG

    Biotech firm developing CRISPR‑based gene editing therapies

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.